Reck, M., Schenker, M., Lee, K.H., et al. (2019) Nivolumab plus Ipilimumab versus Chemotherapy as First-Line Treatment in Advanced Non-Small-Cell Lung Cancer with High Tumour Mutational Burden: Patient-Reported Outcomes Results from the Randomised, Open-Label, Phase III CheckMate 227 Trial. European Journal of Cancer, 116, 137–147.
https://doi.org/10.1016/j.ejca.2019.05.008

has been cited by the following article:

• TITLE: ROS1 in Squamous Non-Small Cell Lung Cancer—Combined Immunotherapy (PD1/CTLA4) or Targeted Therapy?

  AUTHORS: Alexander Yakobson, Tal Mor, Levitas Dina, Laila C. Roisman, Daniel Levin, Wafeek Alguayn, Sara Morgenstern, Keren Rouvinov, Nir Peled, Waleed Kian

  KEYWORDS: ROS1, Crizotinib, Squamous Cell Lung Cancer, Immunotherapy; Non-Small Cell Lung Cancer

  JOURNAL NAME: Journal of Cancer Therapy, Vol.11 No.6, June 11, 2020

  ABSTRACT: ROS1 oncogenic fusion is reported to be 1% - 2% of non-small cell lung cancers (NSCLCs) of the adenocarcinoma subgroup. Meanwhile, there are no records of squamous cell cancer patients with tumors harboring ROS1 fusions. The Foundation Medicine database indicates a frequency of ROS1 rearrangements is 0.2% among squamous NSCLC. Crizotinib is known to be very effective in these patients. Here we present a non-smoker patient who had pure squamous NSCLC that was treated by combinational immunotherapy under a clinical trial and progressed after 2 cycles. Surprisingly, comprehensive genomic profiling detected a rare oncogenic EZR-ROS1 fusion, and the patient was treated by crizotinib with a significant response within 6 weeks. To date, the patient has been on therapy for 42 months and has achieved a complete metabolic response.